Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 102 publications
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 07, 2026
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors.
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: July 16, 2025
Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 05, 2025
Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: Results of the glioblastoma expansion cohort.
Journal: Neuro-oncology advances
Published: May 13, 2025
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer.
Journal: Future oncology (London, England)
Published: October 03, 2024
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.
Journal: The Lancet. Oncology
Published: August 19, 2024
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 31, 2024
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study.
Journal: Journal of immunotherapy and precision oncology
Published: March 14, 2024
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 05, 2024
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial.
Journal: JTO clinical and research reports
Published: March 04, 2024
Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons.
Journal: Clinical lung cancer
Published: February 29, 2024
Last Updated: 09/26/2026